European Heart Journal Advance Access originally published online on June 14, 2007
European Heart Journal 2007 28(13):1598-1660; doi:10.1093/eurheartj/ehm161
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes,
The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members,
(France)
(Germany)
(Italy)
(The Netherlands)
(Poland)
(Spain)
(UK)
(Israel)
(USA)
(Sweden)
(Belgium)
ESC Committee for Practice Guidelines (CPG),
France
(UK)
(Italy)
(France)
(Norway)
(Greece)
(Denmark)
(Czech Republic)
(France)
(Germany)
(Poland)
(The Netherlands)
(Spain)
(Germany)
(France)
Document Reviewers,
(CPG Review Coordinator) ( Denmark)
(Italy)
(Austria)
(France)
(Spain)
(Italy)
(Belgium)
(Germany)
(Spain)
(Germany)
(Israel)
(Austria)
(Israel)
(Spain)
(Portugal)
(Norway)
(Germany)
(France)
(Denmark)
(Italy)
(Canada)
(The Netherlands)
(Switzerland)
* Corresponding authors. Chair: Jean-Pierre Bassand, Department of Cardiology, University Hospital Jean Minjoz, Boulevard Fleming, 25000 Besançon, France. Tel: +33 381 668 539; fax: +33 381 668 582. E-mail address: jean-pierre.bassand@ufc-chu.univ-fcomte.fr Co-chair: Christian W. Hamm Kerckhoff Heart Center, Benekestr. 2-8, 61231 Bad Nauheim, Germany. Tel: +49 6032 996 2202; fax: +49 6032 996 2298. E-mail address: c.hamm@kerckhoff-klinik.de
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.
Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where
 |
Preamble |
|---|
|
1. Introduction and definitions |
|---|
|
2. Epidemiology and natural history |
|---|
|
3. Pathophysiology |
|---|
3.1 The vulnerable plaque
3.2 Coronary thrombosis
3.3 The vulnerable patient
3.4 Endothelial vasodilatory dysfunction
3.5 Accelerated atherosclerosis
3.6 Secondary mechanisms
3.7 Myocardial injury
|
4. Diagnosis and risk assessment |
|---|
4.1 Clinical presentation and history
4.2 Diagnostic tools
4.2.1 Physical examination
4.2.2 Electrocardiogram
Continuous ST-segment monitoring
Exercise or other stress testing
4.2.3 Biochemical markers
Markers of myocardial injury
Markers of inflammatory activity
Markers of neurohumoral activation
Markers of renal function
Novel biomarkers
Multimarker approach
Point-of-care (bedside) biomarker testing
4.2.4 Echocardiography and non-invasive myocardial imaging
4.2.5 Imaging of the coronary anatomy
4.3 Differential diagnoses
4.4 Risk scores
|
5. Treatment |
|---|
5.1 Anti-ischaemic agents
5.1.1 Beta-blockers
5.1.2 Nitrates
5.1.3 Calcium channel blockers
5.1.4 New drugs
5.2 Anticoagulants
5.2.1 Unfractionated heparin
Pharmacology
Treatment effects
5.2.2 Low molecular weight heparin
Pharmacology
Treatment effects
5.2.3 Factor-Xa inhibitors
Pharmacology
Treatment effects
5.2.4 Direct thrombin inhibitors
Pharmacology
Treatment effects
5.2.5 Vitamin K antagonists
5.2.6 Anticoagulants during percutaneous coronary intervention procedures in non-ST-segment elevation acute coronary syndromes
5.3 Antiplatelet agents
5.3.1 Acetylsalicylic acid (aspirin)
5.3.2 Thienopyridines
Risk of bleeding
Dose and timing of clopidogrel
5.3.3 Glycoprotein IIb/IIIa receptor inhibitors
Glycoprotein IIb/IIIa inhibitors in a conservative strategy
Glycoprotein IIb/IIIa inhibitors in an invasive strategy
Use of glycoprotein IIb/IIIa inhibitors prior to revascularization
Adjunctive therapy
5.3.4 Resistance to antiplatelet agents/drug interactions
Aspirin resistance/drug interactions
Clopidogrel resistance/drug interactions
5.3.5 Withdrawal of antiplatelet agents
5.4 Coronary revascularization
5.4.1 Coronary angiography
5.4.2 Invasive vs. conservative strategy
Choice of strategy
Timing of invasiveness
5.4.3 Percutaneous coronary intervention
5.4.4 Coronary artery bypass graft
5.4.5 Respective indications for percutaneous coronary intervention or coronary artery bypass graft
5.5 Long-term management
5.5.1 Lifestyle
5.5.2 Weight reduction
5.5.3 Blood pressure control
5.5.4 Management of diabetes
5.5.5 Interventions on lipid profile
Statins
Other lipid-lowering agents
5.5.6 Antiplatelet agents and anticoagulants
5.5.7 Beta-blockers
5.5.8 Angiotensin-converting enzyme inhibitors
5.5.9 Angiotensin-2 receptor blockers
5.5.10 Aldosterone receptor antagonists
5.6 Rehabilitation and return to physical activity
|
6. Complications and their management |
|---|
6.1 Bleeding complications
6.1.1 Predictors of bleeding risk
6.1.2 Impact of bleeding on prognosis
6.1.3 Management of bleeding complications
6.1.4 Impact of blood transfusion
6.2 Thrombocytopenia
6.2.1 Heparin-induced thrombocytopenia
6.2.2 Glycoprotein IIb/inhibitor-induced thrombocytopenia
|
7. Special populations and conditions |
|---|
7.1 The elderly
7.1.1 Early diagnostic evaluation in the elderly
7.1.2 Therapeutic considerations
7.2 Gender
7.2.1 Glycoprotein IIb/IIIa inhibitors in women
7.2.2 Revascularization and early invasive strategy among women
7.3 Diabetes mellitus
7.4 Chronic kidney disease
7.4.1 Chronic kidney disease as a marker of risk of coronary artery disease
7.4.2 Contrast-induced nephropathy
7.4.3 Management of chronic kidney disease in patients with coronary artery disease
7.4.4 Biomarkers in chronic kidney disease
7.5 Anaemia
7.6 Normal coronary arteries
|
8. Management strategies |
|---|
8.1 First step: initial evaluation
8.2 Second step: diagnosis validation and risk assessment
8.2.1 Diagnosis validation
8.2.2 Risk assessment
8.3 Third step: invasive strategy
8.3.1 Conservative strategy
8.3.2 Urgent invasive strategy
8.3.3 Early invasive strategy
8.4 Fourth step: revascularization modalities
8.5 Fifth step: discharge and post-discharge management
|
9. Performance measures |
|---|
|
10. Abbreviations |
|---|
|
11. Trial acronyms |
|---|
|
Acknowledgements |
|---|
|
Footnotes |
|---|
|
References |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. P. Goran Suggestion to list acute aortic dissection as a possible cause of type 2 myocardial infarction (according to the universal definition) Eur. Heart J., October 3, 2008; (2008) ehn429v1. [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Hermansen, M. Hansen, M. Roaldsen, S. Muller, O.-J. How, and T. Myrmel Utilization and outcome of coronary revascularization and valve procedures in acute heart failure - an evaluation based on the classification from the European Society of Cardiology Interactive CardioVascular and Thoracic Surgery, October 1, 2008; 7(5): 833 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Eggers, T. Kempf, T. Allhoff, B. Lindahl, L. Wallentin, and K. C. Wollert Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain Eur. Heart J., October 1, 2008; 29(19): 2327 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pundziute, J. D. Schuijf, J. W. Jukema, I. Decramer, G. Sarno, P. K. Vanhoenacker, E. Boersma, J. H.C. Reiber, M. J. Schalij, W. Wijns, et al. Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis Eur. Heart J., October 1, 2008; 29(19): 2373 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur. Heart J., October 1, 2008; 29(19): 2388 - 2442. [Full Text] [PDF]
|
|
|
|
|
|
M. Lordkipanidze, C. Pharand, T. A. Nguyen, E. Schampaert, D. A. Palisaitis, and J. G. Diodati Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients Eur. Heart J., September 30, 2008; (2008) ehn419v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hirsch, F. Windhausen, J. G.P. Tijssen, A. J.M. Oude Ophuis, W. J. van der Giessen, P. M. van der Zee, J. H. Cornel, F. W.A. Verheugt, R. J. de Winter, and for the Invasive versus Conservative Treatment in Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias Eur. Heart J., September 29, 2008; (2008) ehn438v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1095 - 1103. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Y H Lip Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention BMJ, September 12, 2008; 337(sep12_1): a840 - a840. [Full Text]
|
|
|
|
 |
|
 P. G. Steg, A. Kerner, F. Van de Werf, J. Lopez-Sendon, J. M. Gore, G. FitzGerald, L. J. Feldman, F. A. Anderson, A. Avezum, and for the Global Registry of Acute Coronary Events ( Impact of In-Hospital Revascularization on Survival in Patients With Non-ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure Circulation, September 9, 2008; 118(11): 1163 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. White, E. M. Ohman, A. M. Lincoff, M. E. Bertrand, A. Colombo, B. T. McLaurin, D. A. Cox, S. J. Pocock, J. A. Ware, S. V. Manoukian, et al. Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial J. Am. Coll. Cardiol., September 2, 2008; 52(10): 807 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Tziakas, G. K. Chalikias, I. K. Tentes, D. Stakos, S. V. Chatzikyriakou, K. Mitrousi, A. X. Kortsaris, J. C. Kaski, and H. Boudoulas Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome Eur. Heart J., September 2, 2008; (2008) ehn382v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ferrari Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular protection Eur. Heart J. Suppl., September 1, 2008; 10(suppl_G): G13 - G20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Pepine Provoked Coronary Spasm and Acute Coronary Syndromes J. Am. Coll. Cardiol., August 12, 2008; 52(7): 528 - 530. [Full Text] [PDF]
|
|
|
|
|
|
R. D. Lopes, K. P. Alexander, G. Marcucci, H. D. White, S. Spinler, J. Col, P. E. Aylward, R. M. Califf, and K. W. Mahaffey Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial Eur. Heart J., August 1, 2008; 29(15): 1827 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Chan, K. W. Mahaffey, L. J. Sun, K. S. Pieper, H. D. White, P. E. Aylward, J. J. Ferguson, R. M. Califf, and M. T. Roe Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 369 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O'Donoghue, W. E. Boden, E. Braunwald, C. P. Cannon, T. C. Clayton, R. J. de Winter, K. A. A. Fox, B. Lagerqvist, P. A. McCullough, S. A. Murphy, et al. Early Invasive vs Conservative Treatment Strategies in Women and Men With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: A Meta-analysis JAMA, July 2, 2008; 300(1): 71 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Schiele, N. Meneveau, and J.-P. Bassand Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer? Eur. Heart J., June 2, 2008; 29(12): 1475 - 1477. [Full Text] [PDF]
|
|
|
|
|
|
H. D. White, D. P. Chew, J. W. Hoekstra, C. D. Miller, C. V. Pollack Jr, F. Feit, A. M. Lincoff, M. Bertrand, S. Pocock, J. Ware, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1734 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Weber and C. Hamm Novel biomarkers--the long march from bench to bedside Eur. Heart J., May 1, 2008; 29(9): 1079 - 1081. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Bassand Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm Heart, May 1, 2008; 94(5): 661 - 666. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bassand Unmet needs in antiplatelet therapy Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D3 - D11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Holmvang and H. Mickley Review: Gender differences following percutaneous coronary intervention Therapeutic Advances in Cardiovascular Disease, April 1, 2008; 2(2): 109 - 113. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Arca, B. Conti, A. Montali, P. Pignatelli, F. Campagna, F. Barilla, G. Tanzilli, R. Verna, A. Vestri, C. Gaudio, et al. C242T Polymorphism of NADPH Oxidase p22phox and Recurrence of Cardiovascular Events in Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 752 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G.G. Turpie Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C1 - C7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bassand The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C22 - C29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Mehta Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C14 - C21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Ruiz-Nodar, F. Marin, J. A. Hurtado, J. Valencia, E. Pinar, J. Pineda, J. R. Gimeno, F. Sogorb, M. Valdes, and G. Y.H. Lip Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation: Implications for Bleeding Risk and Prognosis J. Am. Coll. Cardiol., February 26, 2008; 51(8): 818 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roffi and D. Mukherjee Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era? Eur. Heart J., February 2, 2008; 29(4): 429 - 431. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bassand and C. W. Hamm Non-ST-segment elevation acute coronary syndromes: an algorithm for decision: reply Eur. Heart J., January 2, 2008; 29(2): 280 - 281. [Full Text] [PDF]
|
|
|
|
|
|
O. M. Jolobe Guidelines for the diagnosis and treatment of non-ST segment elevation acute coronary syndromes Eur. Heart J., January 2, 2008; 29(2): 277 - 277. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Bertrand, J. P. Collet, and G. Montalescot Non-ST-segment elevation acute coronary syndromes: an algorithm for decision Eur. Heart J., January 2, 2008; 29(2): 279 - 280. [Full Text] [PDF]
|
|
|
|
|
|
C. Rapezzi, E. Biagini, and A. Branzi Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., January 2, 2008; 29(2): 277 - 278. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Gitt and A. Betriu Antiplatelet therapy in acute coronary syndromes Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A4 - A12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Giannitsis and H. A. Katus Ability of DNase I activity to detect myocardial ischaemia in vasospastic angina a view through a monocle? Eur. Heart J., December 2, 2007; 28(24): 2955 - 2956. [Full Text] [PDF]
|
|
|
|
|
|
A. V Hernandez, C. M Westerhout, E. W Steyerberg, J. P A Ioannidis, H. Bueno, H. White, P. Theroux, D. J Moliterno, P. W Armstrong, R. M Califf, et al. The authors' reply: Heart, October 1, 2007; 93(10): 1293 - 1293. [Full Text] [PDF]
|
|